New Competitive Intelligence Reports on Targeted Therapeutics for Various Diseases Published by MarketPublishers.com

21 Sep 2011 • by Natalie Aster
New Competitive Intelligence Reports on Targeted Therapeutics for Various Diseases Published by MarketPublishers.com

LONDON - Market Publishers Ltd informs that new in-demand La Merie SL reports on the R&D pipelines of targeted therapeutics in various diseases have been added to its catalogue.

Competitor Analysis: Targeted Therapy of Hepatitis C. The report presents a competitor assessment in the area of specifically targeted antiviral therapeutics for hepatitis C (STAT-C). The study also contains a compilation of current active projects in research and development of molecules specifically directed against novel targets in hepatitis C. A list of company-specific R&D pipelines of targeted therapeutics in hepatitis C is incorporated in the study as well …

Competitor Analysis: HDAC Inhibitors. Histone deacetylase (HDAC) inhibitors are emerging as a new class of potential anticancer agents for the treatment of solid and hematological malignancies. The report focuses on the competitor analysis in the development pipeline of novel molecular entities inhibiting HDAC for treatment of cancer and other diseases …

Competitor Analysis: Novel Mitotic Kinase Inhibitors. Mitosis, a central event in tumor growth, is highly regulated to ensure accurate and equal segregation of genetic materials from parent cells to daughter cells. Main effectors of this process are mitotic spindles and centrosomes. The report provides a competitor evaluation in the field of synthetic molecules targeting polo-like kinase 1 (Plk-1), cyclin-dependent kinase (CDK) or aurora kinase for treatment of cancer …

Competitor Analysis: Her2 and Her3 Receptor Antagonists. The commercial success of Herceptin (trastuzumab) and the development of resistance to trastuzumab treatment has spurred the discovery and development of efficacy enhanced versions of anti-Her2 antibodies or antibodies binding to an epitope different from that of trastuzumab. The report offers a competitor evaluation in the field of Her2 (ErbB2) and Her3 receptor targeting molecules for treatment of cancer …

Competitor Analysis: IGF-1R Antagonists. The study presents a competitor analysis in the development pipeline of novel molecular entities directed against the insulin-like growth factor-1 receptor (IGF-1R) or its ligands IGF-1 and IGF-2 for treatment of cancer. It includes a collection of current active projects in R&D of IGF-1/R antagonists in oncology. Moreover, company-specific R&D pipelines of IGF-1/R antagonists can also be found in the report …

More new publisher’s research reports can be found at La Merie SL page.

 

CONTACTS

The Market Publishers, Ltd.

Tanya Rezler

Tel: +44 208 123 2220

Fax: +44 207 900 3970

ps@marketpublishers.com

www.marketpublishers.com